Validation of Neuroimaging Technology Platform
IXICO plc has presented new data validating its IXI™ Platform's automated neuroimaging capabilities, demonstrating that its automated measurement of brain volume loss on MRI matches or exceeds the performance of traditional semi-manual methods like the Boundary Shift Integral (BSI). In a study with a US pharmaceutical partner, the IXI™ Platform proved most sensitive in detecting whole brain and caudate volume loss, offering a more cost-effective and scalable solution for clinical trials in neurological disorders, particularly Huntington's Disease. This advancement is expected to reduce operational burdens and increase sensitivity in detecting brain changes, potentially impacting future drug development programs.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
26 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announced it has presented new data demonstrating that automated capabilities to measure brain volume loss on magnetic resonance imaging (MRI) within its IXI™ Platform are at a minimum matching, and in some measures exceeding, the performance of semi-manual methods which require manual analysis by (human) experts.
The accurate measurement of brain volume shrinkage (brain atrophy), caused by the loss of brain cells and the breakdown of connections between them, is fundamental to developing new treatments for a number of neurodegenerative diseases, including Huntington's Disease (HD). Traditionally, researchers have relied on a semi-manual approach to measure brain volume loss, known as the Boundary Shift Integral (BSI) which is currently considered to be the 'gold standard' method of analysis.
In a recent study conducted by IXICO and a large US pharmaceutical partner, the results show that automated capabilities to measure brain atrophy on MRI within its IXI™ Platform match or exceed the performance of the semi-manual BSI method, providing an advanced, cost-effective and scalable solution to support clinical trials in HD. Of the three approaches evaluated to measure brain atrophy, IXI™ demonstrated it was the most sensitive method for detecting whole brain and caudate (a small region deep in the brain impacted early in HD) volume loss.
A full summary of the study and more detail on the data presented is available on IXICO's website by following this link. The data is being presented in a scientific poster at the 21st Annual Huntington's Disease Therapeutics Conference in California, USA this week (23-26 February 2026).
Robin Wolz, Chief Scientific Officer of IXICO, commented: "By using a scalable, sensitive AI imaging analysis approach such as on our IXITM Platform, researchers can reduce the operational burden of semi-manually analysed images and increase sensitivity to detecting changes in the brain. It is my belief that this has huge potential to impact how biomarker analyses inform the next generation of drug development programs in neurodegenerative disease".
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.